| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9925157 | HORIZON PHARMA USA | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(3 years from now) | |
| US9198882 | HORIZON PHARMA USA | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(3 years from now) | |
| US9192590 | HORIZON PHARMA USA | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(3 years from now) | |
| US9925156 | HORIZON PHARMA USA | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(3 years from now) | |
| US9925158 | HORIZON PHARMA USA | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(3 years from now) | |
|
US9192590 (Pediatric) | HORIZON PHARMA USA | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
|
US9198882 (Pediatric) | HORIZON PHARMA USA | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
| US8026284 | HORIZON PHARMA USA | Enterically coated cystamine, cysteamine and derivatives thereof |
Sep, 2027
(3 years from now) | |
|
US8026284 (Pediatric) | HORIZON PHARMA USA | Enterically coated cystamine, cysteamine and derivatives thereof |
Mar, 2028
(4 years from now) | |
| US9233077 | HORIZON PHARMA USA | Delayed release cysteamine bead formulation, and methods of making and using same |
Jun, 2034
(10 years from now) | |
| US9173851 | HORIZON PHARMA USA | Delayed release cysteamine bead formulation, and methods of making and using same |
Jun, 2034
(10 years from now) | |
|
US9233077 (Pediatric) | HORIZON PHARMA USA | Delayed release cysteamine bead formulation, and methods of making and using same |
Dec, 2034
(11 years from now) | |
|
US9173851 (Pediatric) | HORIZON PHARMA USA | Delayed release cysteamine bead formulation, and methods of making and using same |
Dec, 2034
(11 years from now) | |
| US10328037 | HORIZON PHARMA USA | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(12 years from now) | |
| US10548859 | HORIZON PHARMA USA | Methods for storing Cysteamine formulations and related methods of treatment |
Aug, 2036
(12 years from now) | |
| US10905662 | HORIZON PHARMA USA | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(12 years from now) | |
| US10143665 | HORIZON PHARMA USA | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(12 years from now) | |
Procysbi is owned by Horizon Pharma Usa.
Procysbi contains Cysteamine Bitartrate.
Procysbi has a total of 17 drug patents out of which 0 drug patents have expired.
Procysbi was authorised for market use on 14 February, 2020.
Procysbi is available in granule, delayed release;oral dosage forms.
Procysbi can be used as management of nephropathic cystinosis by administering a total daily dose in two divided doses.
The generics of Procysbi are possible to be released after 16 August, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE* (ODE*) | Dec 22, 2024 |
| Pediatric Exclusivity (PED) | Jun 22, 2025 |
Drugs and Companies using CYSTEAMINE BITARTRATE ingredient
Market Authorisation Date: 14 February, 2020
Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Dosage: GRANULE, DELAYED RELEASE;ORAL
PROCYSBI family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9925158 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(3 years from now) | |
| US9925157 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(3 years from now) | |
| US9925156 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9192590 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(3 years from now) | |
| US9198882 | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jan, 2027
(3 years from now) | |
|
US9925158 (Pediatric) | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
|
US9925156 (Pediatric) | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
|
US9925157 (Pediatric) | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
|
US9198882 (Pediatric) | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
|
US9192590 (Pediatric) | HORIZON | Enterically coated cysteamine, cystamine and derivatives thereof |
Jul, 2027
(3 years from now) | |
| US8026284 | HORIZON | Enterically coated cystamine, cysteamine and derivatives thereof |
Sep, 2027
(3 years from now) | |
|
US8026284 (Pediatric) | HORIZON | Enterically coated cystamine, cysteamine and derivatives thereof |
Mar, 2028
(4 years from now) | |
| US9233077 | HORIZON | Delayed release cysteamine bead formulation, and methods of making and using same |
Jun, 2034
(10 years from now) | |
| US9173851 | HORIZON | Delayed release cysteamine bead formulation, and methods of making and using same |
Jun, 2034
(10 years from now) | |
|
US9233077 (Pediatric) | HORIZON | Delayed release cysteamine bead formulation, and methods of making and using same |
Dec, 2034
(11 years from now) | |
|
US9173851 (Pediatric) | HORIZON | Delayed release cysteamine bead formulation, and methods of making and using same |
Dec, 2034
(11 years from now) | |
| US10905662 | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(12 years from now) | |
| US10548859 | HORIZON | Methods for storing Cysteamine formulations and related methods of treatment |
Aug, 2036
(12 years from now) | |
| US10328037 | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(12 years from now) | |
| US10143665 | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(12 years from now) | |
|
US10905662 (Pediatric) | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Feb, 2037
(13 years from now) | |
|
US10548859 (Pediatric) | HORIZON | Methods for storing Cysteamine formulations and related methods of treatment |
Feb, 2037
(13 years from now) | |
|
US10328037 (Pediatric) | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Feb, 2037
(13 years from now) | |
|
US10143665 (Pediatric) | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Feb, 2037
(13 years from now) | |
Procysbi is owned by Horizon.
Procysbi contains Cysteamine Bitartrate.
Procysbi has a total of 24 drug patents out of which 0 drug patents have expired.
Procysbi was authorised for market use on 30 April, 2013.
Procysbi is available in capsule, delayed release;oral dosage forms.
Procysbi can be used as management of nephropathic cystinosis by administering a total daily dose in two divided doses.
The generics of Procysbi are possible to be released after 16 February, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 22, 2024 |
| Pediatric Exclusivity (PED) | Jun 22, 2025 |
Drugs and Companies using CYSTEAMINE BITARTRATE ingredient
Market Authorisation Date: 30 April, 2013
Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Dosage: CAPSULE, DELAYED RELEASE;ORAL
PROCYSBI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic